ARTICLE

FindCenter AddIcon

A Conversation with Albert Hofmann

By Charles Grob — 1996

On November 26, 1996, Charles Grob, M.D. visited with Albert Hofmann in Rheinfelden, outside of Basel, Switzerland, where Dr. Hofmann was recovering from knee surgery. The following are excerpts from their conversation.

Read on maps.org

FindCenter Post-Image

Psychedelic Psychotherapy Is Coming: Who Will Be Included?

A new study finds widespread exclusion of minorities in psychedelic research.

Article
Monnica T. Williams
2018
FindCenter AddIcon
FindCenter Post-Image

How Researchers and Advocates of Color Are Forging Their Own Paths in Psychedelic-Assisted Therapy

We’re seeing an explosion of medical research into psychedelics. Psilocybin, or shrooms, to treat major depressive disorder. Ayahuasca, a psychotropic plant medicine from the Amazon, and ibogaine, a potent hallucinogen from Africa, to treat addiction. LSD for anxiety.

Article
Steph Yin
2020
FindCenter AddIcon
FindCenter Post-Image

Study Finds Ketamine Can Help Patients Manage Depression and PTSD

Through this treatment plan, the patient was able to “reconceptualize her trauma” and “was able to move through difficult memories and emotions rather than letting them consume her,” explained U of O associate professor, Monnica Williams.

Article
Hannah Sabourin
2021
FindCenter AddIcon
FindCenter Post-Image

Who Will Benefit From Psychedelic Medicine?

These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.

Article
Whitney Joiner
2020
FindCenter AddIcon
FindCenter Post-Image

Psychedelics Shown to Ease the Effects of Racial Trauma

A recent study found that even a single positive psychedelic experience may ease mental health symptoms associated with racial trauma experienced by Black, Indigenous, and people of color (BIPOC).

Article
Kristi Pahr
2021
FindCenter AddIcon
FindCenter Post-Image

Seismic Sisters: Fighting Stigma of Psychedelics with Science - An Interview with Natalie Ginsberg, Policy and Advocacy Director at Multidisciplinary Association for Psychedelic Studies

Society has started to become more accepting of our work and MAPS’ goal of mainstreaming psychedelic medicine seems closer than ever to being achieved,” explains MAPS Policy and Advocacy Director Natalie Ginsberg, M.S.W., in an interview with Jessica Semaan of Seismic Sisters.

Article
Jessica Semaan
2020
FindCenter AddIcon
FindCenter Post-Image

What Ails Us

Most genetic studies completely ignore the science of epigenetics, which is how the environment actually turns certain genes on or off.

Article
Tracy Frisch, Gabor Mate
2012
FindCenter AddIcon
FindCenter Post-Image

A Psychotherapeutic View on the Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Addiction

In an appropriate context, ayahuasca can be a valuable therapeutic tool and can act as a catalyst that can render psychotherapeutic processes more effective in less time, and sometimes allow for critical interventions when several other therapeutic strategies have been unsuccessful.

Article
Anja Loizaga-Velder
2013
FindCenter AddIcon
FindCenter Post-Image

5 Women in Psychedelics You Should Know About

Badass women making waves in the psychedelic movement, from research to drug policy reform.

Article
Michelle Janikian
2019
FindCenter AddIcon
FindCenter Post-Image

Psilocybin Therapy May Work as Well as Common Antidepressant

The first randomized controlled trial to compare the illicit psychedelic psilocybin with a conventional selective serotonin reuptake inhibitor (SSRI) antidepressant found that the former improved symptoms of depression just as well on an established metric—and had fewer side effects.

Article
Zoe Cormier
2021
FindCenter AddIcon

EXPLORE TOPIC

LSD